Navigation Links
Periodic in Biological Technology

InterMune Reports Second Quarter 2009 Financial Results and Business Highlights

... Form 10-K filed with the SEC on March 16, 2009 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) the fact that ... other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web ...

Senesco Technologies Enters Into Agreements For Additional $700,000 In Financing

... as well as other factors expressed from time to time in the Company's periodic filings with the SEC. As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are ...

Zimmer Launches New Medical Education and BioSkills Training Program

... a further list and description of such risks and uncertainties, see our periodic reports filed with the U.S. Securities and Exchange Commission. We ... information, future events or otherwise, except as may be set forth in our periodic reports. Readers of this document are cautioned not to place undue ...

Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing

... as well as other factors expressed from time to time in the Company's periodic filings with the SEC. As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are ...

ArborGen and Senesco Announce Wood Quality Results

... AMEX, as well as other factors expressed from time to time in Senesco's periodic filings with the Securities and Exchange Commission (the " SEC" ). As a result, this press release should be read in conjunction with Senesco's periodic filings with the SEC. The forward-looking statements contained herein are ...

Senesco Technologies, Inc. Announces the Appointment of Dr. Harlan W. Waksal, M.D. as Chairman of the Board of Directors and the Addition of Mr. Warren J. Isabelle, CFA to its Board of Directors

... as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the " SEC" ). As a ... this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are ...

Senesco Presents Pre-Clinical Multiple Myeloma Data at the 12th Annual Meeting of the American Society of Gene Therapy

... as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are ...

Poniard Pharmaceuticals Files Shelf Registration

... is intended to provide the Company with flexibility to facilitate the periodic sale of its securities, subject to market conditions and the Company's ... and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including ...

Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS

... Form 10-K filed with the SEC on March 16, 2009 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related ... other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web ...

Senesco Technologies Reports Third Quarter Fiscal 2009 Financial Results

... as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are ...

United Therapeutics Reports First Quarter 2009 Financial Results

... subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could ... statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, ...

InterMune Reports First Quarter 2009 Financial Results and Business Highlights

... Form 10-K filed with the SEC on March 16, 2009 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) the fact that ... other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web ...

INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients

... Form 10-K filed with the SEC on March 16, 2009 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to ... other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web ...

InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting

... Form 10-K filed with the SEC on March 16, 2009 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to ... other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web ...

INFORM-1 Interim Results Accepted for Late-Breaker Presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)

... Form 10-K filed with the SEC on March 16, 2009 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to ... other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web ...

Palatin Technologies' Listing Compliance Plan Accepted by NYSE Alternext US

... on the Exchange during the plan period through June 23, 2010, subject to periodic review by the Exchange to determine if Palatin is making progress ... its intellectual property, and other factors discussed in the Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not ...

InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights

... Form 10-K filed with the SEC on March 14, 2008 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) the fact that ... other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web ...

InterMune Announces Issuance of U.S. Patent for ITMN-191

... Form 10-K filed with the SEC on March 14, 2008 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related ... other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web ...

Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results

... as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the " SEC" ). As a ... this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are ...

InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock

... Form 10-K filed with the SEC on March 14, 2008 (the "Form 10-K") and other periodic reports filed with the SEC. Completion of the offering is subject to ... other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web ...

InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF

... Form 10-K filed with the SEC on March 14, 2008 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related ... other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web ...

Palatin Technologies Receives Notification Letter from NYSE Alternext US

... its listing during the plan period through July 23, 2010, subject to periodic review by the Exchange to determine if it is making progress consistent ... its intellectual property, and other factors discussed in the Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not ...

Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring

... as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are ...

Surface plasmon resonances of metal nanoparticles in array can have narrower spectral widths

... that the surface plasmon resonances of metal nanoparticles in a periodic array can have considerably narrower spectral widths than those of ... Further, as the optical fields are significantly more intense in a periodic array, the method could improve the sensitivity of detecting molecules at ...

InterMune Reports Third Quarter 2008 Financial Results and Business Highlights

... Form 10-K filed with the SEC on March 14, 2008 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) the fact that ... other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web ...

United Therapeutics Reports Third Quarter 2008 Financial Results

... subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could ... statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, ...

InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF

... Form 10-K filed with the SEC on March 14, 2008 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to ... other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web ...

InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting

... Form 10-K filed with the SEC on March 14, 2008 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to ... other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web ...

Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology

... a further list and description of such risks and uncertainties, see our periodic reports filed with the U.S. Securities and Exchange Commission. We ... information, future events or otherwise, except as may be set forth in our periodic reports. Readers of this document are cautioned not to place undue ...

InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche

... Form 10-K filed with the SEC on March 14, 2008 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to ... other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web ...

Watson Pharmaceuticals Reports Second Quarter 2008 Results

... mix between the Company's Brand, Generic and Distribution business units; periodic dependence on a small number of products for a material source of net ... products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but ...

InterMune Reports Second Quarter 2008 Financial Results and Business Highlights

... Form 10-K filed with the SEC on March 14, 2008 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) the fact that ... other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web ...

United Therapeutics Reports Second Quarter 2008 Financial Results

... subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could ... statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, ...

Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct

... Form 10-K filed with the SEC on March 14, 2008 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to ... other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web ...

Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook

... mix between the Company's Brand, Generic and Distribution business units; periodic dependence on a small number of products for a material source of net ... products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but ...

Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing

... as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are ...

Zimmer Holdings Announces Support for Elimination of Super-Majority Voting Requirements

... a further list and description of such risks and uncertainties, see our periodic reports filed with the U.S. Securities and Exchange Commission. We ... information, future events or otherwise, except as may be set forth in our periodic reports. Readers of this document are cautioned not to place undue ...

Two-faced miniatures

... micrometers wide). The bottom portion of the device is a phase mask with a periodic surface structure. This arrangement is irradiated through a transparency ... with sides of 60 m. Once the parallel light rays pass through the strictly periodic surface structure of the phase mask, the result is a complex ...

Zimmer Announces Settlement of Federal Investigation

... a further list and description of such risks and uncertainties, see our periodic reports filed with the U.S. Securities and Exchange Commission. We ... information, future events or otherwise, except as may be set forth in our periodic reports. Readers of this document are cautioned not to place undue ...

Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products

... a further list and description of such risks and uncertainties, see our periodic reports filed with the U.S. Securities and Exchange Commission. We ... information, future events or otherwise, except as may be set forth in our periodic reports. Readers of this document are cautioned not to place undue ...
Other Contents
(Date:7/10/2014)... HUNTINGTON, W.Va. The Marshall Institute for Interdisciplinary ... Edwards School of Medicine today announced they will ... develop potential anti-cancer drugs. , Under the agreement ... partners will share the costs and risks of ... also will jointly own any intellectual property and ...
(Date:7/10/2014)... Endomedix, a start-up company housed at NJIT,s business incubator, ... spray-on gel that surgeons will use to staunch bleeding ... onto a surgical site, and the natural bio-polymer solutions ... the patient within 30 seconds. , The gel ... It will translate into less time for the patient,s ...
(Date:7/10/2014)... diseases, such as Alzheimer,s disease, type 2 diabetes, ... common trait that proteins aggregate into long fibers ... have found that neither the amylin monomer precursors ... evidence using two-dimensional infrared (2D IR) spectroscopy has ... pathway that may explain toxicity, opening a window ...
Breaking Biology News(10 mins):Marshall University to partner with international company in drug development venture 2A start-up at NJIT develops bleeding-control gel for brain surgery 2New technology reveals insights into mechanisms underlying amyloid diseases 2
(Date:7/11/2014)... Even the hot Texas sun won’t keep ... . The school had previously invested in a ... from APCPLAY, but recently asked for an innovative solution to ... Godley Elementary School chose a Rectangular Shade from APCPLAY as ... on their playground. The shade measures 24’W x 34’H ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Based in ... care to residents of Brazoria County and surrounding counties. ... the clinic is now accessible from Northbound Highway 288 ... a center where patients can get low-cost urgent care ... far from rare, finding places that can match the ...
(Date:7/10/2014)... 2014 Fatigue, lack of safety ... number of accidents in the workplace, according to ... articles highlight safety issues that contribute to the ... occur on the job annually, according to the ... explore "preventable workplace accidents." , Safety Issue: "Extended ...
(Date:7/10/2014)... 2014 According to a new ... Platforms (Land, Airborne, Naval), Application (Software Defined Radios, ... Geography (North America, Asia-Pacific, Europe, the Middle East ... by MarketsandMarkets, the market is estimated to be ... register a CAGR of 5.56% to reach $39.52 ...
(Date:7/10/2014)... 2014 Parker Waichman LLP, a ... of victims injured by defective medical devices, reports ... allegations that the woman’s hidden, aggressive leiomyosarcoma was ... used during a routine laparoscopic supracervical hysterectomy procedure. ... Medical Instruments Corporation over its Wolf Power Morcellator ...
Breaking Medicine News(10 mins):Health News:Cool Fun Under the Texas Sun: Godley Elementary School Purchases Shade Structure from APCPLAY© 2Health News:Prime Urgent Care Announces New Access to the Clinic, Available from Northbound Highway 288 2Health News:Safety Reboot Magazine Focuses on: Why Extended Hours is Dangerous in the Workplace; Why Custodial Work Can be Dangerous; and Improving Safety for Roofers 2Health News:Safety Reboot Magazine Focuses on: Why Extended Hours is Dangerous in the Workplace; Why Custodial Work Can be Dangerous; and Improving Safety for Roofers 3Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 3Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 4Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 5
Other TagsOther Tags